Jiaci

73 / 80

J Investig Allergol Clin Immunol 2019; Vol. 29(5): 399-400 © 2019 Esmon Publicidad
doi: 10.18176/jiaci.0414
Selection of Biologics for Type-2 High Severe Asthma
Manuscript received April 8, 2019; accepted for
publication May 7, 2019.
Insu Yilmaz
Erciyes University School of Medicine
Department of Chest Diseases
Division of Immunology and Allergy
Kayseri, Turkey
E-mail:
trials comparing efficacy and combination trials with anti-IgE
and anti-IL5/anti-IL5R are lacking and should be performed
in the near future.
Funding
The author declares that no funding was received for the
present study.
Conflicts of Interest
The author declares that he has no conflicts of interest.
References
1. Sánchez-Jareño M, Barranco P, Romero D, Domínguez-Ortega
J, Quirce S. Severe Eosinophilic Allergic Asthma Responsive
to Mepolizumab After Failure of 2 Consecutive Biologics. J
Investig Allergol Clin Immunol. 2019;29(1):79-81.
2. Adolescent and adults with difficult-to-treat and severe
asthma, GINA 2018.
3. Bleecker ER, Wechsler ME, Fitz Gerald JM, Menzies-Gow A,
Wu Y, Hirsch I, et al. Baseline Patient Factor Impact on the
Clinical Efficacy of Benralizumab for Severe Asthma. Eur
Respir J. 2018;52:1800936.
4. Dávila I, Quirce S, Olaguibel JM. Selection of biologics in
severe asthma: a multifaceted algorithm. J Investig Allergol
Clin Immunol. 2019;29(4):325-8. doi: 10.18176/jiaci.0398.
5. Froidure A, Mouthuy J, Durham SR, Chanez P, Sibille Y, Pilette
C. Asthma phenotypes and IgE responses. Eur Respir J.
2016;47:304-19.
6. Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides
S, Gaga M. An algorithmic approach for the treatment of
severe uncontrolled asthma. ERJ Open Res. 2018;4:00125-
2017.
7. Oishi K, Matsunaga K. Three-step algorithm for biological
therapy targeted IgE and IL-5 in severe asthma. Immun
Inflamm Dis. 2018;6(3):374-6.
8. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in
Asthma. Am J Respir Crit Care Med. 2019;199(4):433-45.
9. Bel EH,Wenzel SE,Thompson PJ, Prazma CM, Keene ON,Yancey
SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in
eosinophilic asthma. N Engl J Med. 2014;371:1189-97.
10. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight:
eosinophilic airway inflammation in nonallergic asthma. Nat
Med. 2013;19:977-9.
11. Barnes PJ. Intrinsic asthma: Not so different from allergic
asthma but driven by superantigens? Clin Exp Allergy.
2009;39:1145-51.
12. Cahill KN, Boyce JA. Aspirin-exacerbated respiratory disease:
Mediators and mechanisms of a clinical disease. J Allergy Clin
Immunol. 2017;139(3):764-6.
13. Yilmaz I, Terl M. Asthma management: A new phenotype-
based approach using presence of eosinophilia and allergy.
Allergy. 2017;72(10):1587-9.
400